Enzymotec Ltd. Granted New Patents in the United States and Australia Relevant to Phospholipid-Based Products
March 13 2015 - 8:47AM
Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a
developer, manufacturer and marketer of innovative bio-active lipid
ingredients, announced today that it has been granted new patents
by the U.S. Patent and Trademark Office and the Australian Patent
Office for certain phospholipid-based compositions that cover
several of the Company's products.
The granted patents cover a wide variety of phospholipid based
compositions that include long chain poly-unsaturated fatty acids,
and are pertinent to a number of Enzymotec's products, such as the
K•REAL® krill oil products and additional advanced phospholipid
products. These additions to Enzymotec's broad patent portfolio are
the result of the Company's efforts to continually maintain and
reinforce the protection of its products.
Dr. Ariel Katz, President and Chief Executive Officer of
Enzymotec, commented, "As experts in specialty phospholipid-based
products, we are excited by the further strengthening of our
portfolio of intellectual property with these important patents.
Our products are strong leaders in the market, driven by our
specialized technologies and supported with an enforceable patent
portfolio. These new patents are demonstrative of our commitment to
innovation and provide our customers with exceptional ingredients
of the highest quality."
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based
products and solutions. The Company develops, manufactures and
markets innovative bio-active lipid ingredients, as well as final
products, based on sophisticated processes and technologies. For
more information, visit www.enzymotec.com
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences include the following risks: A high proportion of
the sales of the InFat product is sold to end users in China and to
a single company; The demand for products based on Omega-3 and in
particular, premium products, such as krill oil, has declined and
may continue to decline following a significant increase in
manufacturing capacity by manufacturers of these products,
resulting in intense competition and price pressure; Our offering
of products as "medical foods" in the United States may be
challenged by regulatory authorities; We rely on our Swedish joint
venture partner to manufacture InFat and certain matters related to
the joint venture are the subject of disagreement in arbitration
proceeding; We are subject to a degree of customer concentration
and our customers do not enter into long-term purchase commitments
with us; We depend on third parties to obtain raw materials, in
particular krill, necessary for the production of our products; We
are dependent on a single facility that houses the majority of our
operations; We may have to pay royalties with respect to sales of
our krill oil products in the United States or Australia and any
infringement of intellectual property of others could also require
us to pay royalties; Potential future acquisitions of companies or
technologies may distract our management, may disrupt our business
and may not yield the returns expected; We anticipate that the
markets in which we participate will become more competitive and we
may be unable to compete effectively; We may not be able to
successfully expand our production or processing capabilities; Our
ability to obtain krill may be affected by conservation regulation
or initiatives; Our product development cycle is lengthy and
uncertain, and our development or commercialization efforts for our
products may be unsuccessful; and other factors discussed under the
heading "Risk Factors" in the Company's Form 20-F filed with the
Securities and Exchange Commission on March 2, 2015.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: KCSA Strategic Communications
Jeffrey Goldberger / Tram Bui
212.896.1249 / 212.896.1290
ENZY@kcsa.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024